European Journal of Heart Failure, Год журнала: 2023, Номер 25(11), С. 1887 - 1890
Опубликована: Ноя. 1, 2023
Язык: Английский
ESC Heart Failure, Год журнала: 2024, Номер unknown
Опубликована: Май 28, 2024
Abstract In the last years, major progress has occurred in heart failure (HF) management. The 2023 ESC focused update of 2021 HF guidelines introduced new key recommendations based on results years science. First, two drugs, sodium–glucose co‐transporter‐2 (SGLT2) inhibitors and finerenone, a novel nonsteroidal, selective mineralocorticoid receptor antagonist (MRA), are recommended for prevention patients with diabetic chronic kidney disease (CKD). Second, SGLT2 now treatment across entire left ventricular ejection fraction spectrum. benefits quadruple therapy reduced (HFrEF) well established. Its rapid early up‐titration along close follow‐up frequent clinical laboratory re‐assessment after an episode acute (the so‐called ‘high‐intensity care’ strategy) was associated better outcomes STRONG‐HF trial. Patients experiencing worsening might require fifth drug, vericiguat. STEP‐HFpEF‐DM STEP‐HFpEF trials, semaglutide 2.4 mg once weekly administered 1 year decreased body weight significantly improved quality life 6 min walk distance obese preserved (HFpEF) or without history diabetes. Further data safety efficacy, including also hard endpoints, needed to support addition acetazolamide hydrochlorothiazide standard diuretic regimen hospitalized due HF. meantime, PUSH‐AHF supported use natriuresis‐guided therapy. options most recent evidence HF, specific drugs cardiomyopathies (i.e., mavacamten hypertrophic cardiomyopathy tafamidis transthyretin cardiac amyloidosis), device therapies, contractility modulation percutaneous valvulopathies, finding from TRILUMINATE Pivotal trial, reviewed this article.
Язык: Английский
Процитировано
38
European Journal of Heart Failure, Год журнала: 2023, Номер 26(2), С. 327 - 337
Опубликована: Ноя. 7, 2023
Persistent symptoms despite guideline-directed medical therapy (GDMT) and poor tolerance of GDMT are hallmarks patients with advanced heart failure (HF) reduced ejection fraction (HFrEF). However, real-world data on use, dose, prognostic implications lacking.
Язык: Английский
Процитировано
27
Journal of Cardiac Failure, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
During the last century characteristics of patients with heart failure (HF) and acute HF (AHF) have shifted from severe pump due to rheumatic, hypertensive ischemic disease older more obese multiple comorbidities. The pathophysiology AHF has in parallel that advanced, end-stage, caused by left ventricular dysfunction age, obesity comorbidity-related cardiovascular combined neurohormonal inflammatory dysregulation or "inflammaging". With advent blockers leading improved outcomes chronic HF, focus therapy also changed care directed at early symptom improvement therapies towards longer-term improvements quality life outcomes. Studies conducted 5 years suggest beneficial effects seen 4 pillars guideline-directed medical for mostly comprising blockade, can be extended when these are initiated rapidly uptitrated during admission after discharge. A recent pilot study (CORTAHF) suggested benefits treating markers activation anti-inflammatory therapies. Future studies should further examine whether blockade lead reversal disrupted underlying remission AHF.
Язык: Английский
Процитировано
1
European Journal of Heart Failure, Год журнала: 2024, Номер 26(3), С. 638 - 651
Опубликована: Март 1, 2024
Язык: Английский
Процитировано
6
European Journal of Clinical Investigation, Год журнала: 2024, Номер 54(4)
Опубликована: Янв. 18, 2024
DT reports personal fees from Alnylam Pharmaceuticals, Boehringer Ingelheim and Pfizer outside the submitted work. MA speaker Abbott Vascular Medtronic. MM consulting honoraria of minimal amount Abbott, Amgen, Bayer, Edwards Therapeutics, LivaNova Vifor Pharma for participation to advisory board meetings executive committees clinical trials. All other authors have no conflicts interest disclose.
Язык: Английский
Процитировано
4
European Journal of Emergency Medicine, Год журнала: 2024, Номер 31(4), С. 231 - 233
Опубликована: Июнь 25, 2024
aDepartment of Anesthesia-Reanimation, Cavale Blanche Hospital bLaboratoire ORPHY EA 4324, University Brest, France cClinic Cardiac and Vascular Diseases, Institute Clinical Medicine, Faculty Vilnius University, Vilnius, Lithuania dINSERM UMR-S 942 Paris eDepartment Lariboisière Hospital, Paris, Received 22 May 2024 Accepted 24 2024. Correspondence to Anais Caillard, MD, PhD, Department 29609 Boulevard Tanguy Prigent, 29200 Tel: +332 98 34 72 84; e-mail: [email protected]
Язык: Английский
Процитировано
3
Journal of Clinical Medicine, Год журнала: 2025, Номер 14(10), С. 3611 - 3611
Опубликована: Май 21, 2025
Background: The 2023 ESC Heart Failure (HF) Guidelines recommend the rapid up-titration of guideline-directed medical therapy (GDMT) for all patients after HF hospitalisation. Real-world data on implementation a programme (RTP) are scarce. Methods: We aimed to summarise primary experiences six-week RTP in multicentre observational study five cardiology centres, evaluating GDMT applied and target doses (TDs) achieved during RTP. safety relation exceeding “safety indicators” used STRONG-HF trial any serious adverse events were observed. Changes left ventricular ejection fraction (LVEF) evaluated. Results: Among 90 consecutive (age: 56 [49–63] years, HFrEF: 96%, NT-proBNP at discharge: 1390 [735–2835] pg/mL; continuous variables presented as median interquartile ranges, while categorical shown absolute numbers percentages, respectively), remarkable proportion received hospital discharge; however, rarely (RASi: 100%, TD RASi: 11%; βB: 97%, 6%; MRA: 99%, 82%; SGLT2i: 98%, 98%; triple [TT: RASi + βB MRA]: TT: 2%, quadruple [QT: 94%, QT: 2%). After RTP, 100% total cohort (TC) receiving RASi; 99–99–99% βB, MRA, SGLT2i medications; altogether, 98–98% TT QT. In total, 78–78% ≥50% TDs QT, 51–51% TC During no Between two four months 51% HFrEF evolved HFimpEF category. Conclusions: present multicentre, confirms that is feasible safe real-world clinical practice, leading remarkably large by end resulting significant increase LVEF.
Язык: Английский
Процитировано
0
Circulation Heart Failure, Год журнала: 2024, Номер 17(4)
Опубликована: Апрель 1, 2024
Язык: Английский
Процитировано
2
Heart Failure Reviews, Год журнала: 2024, Номер 29(5), С. 1065 - 1077
Опубликована: Июль 22, 2024
Heart failure (HF) is a systemic disease associated with high risk of morbidity, mortality, increased hospitalizations, and low quality life. Therefore, effective, treatment strategies are necessary to mitigate these risks. In this manuscript, we emphasize the concept high-intensity care optimize guideline-directed medical therapy (GDMT) in HF patients. The document highlights importance achieving optimal recommended doses GDMT medications, including beta-blockers, renin-angiotensin-aldosterone inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter inhibitors improve patient outcomes, achieve sustainable decongestion, also discusses potential obstacles optimization, such as clinical inertia, physiological limitations, comorbidities, non-adherence, frailty. Lastly, it attempts provide possible future scenarios high-intensive that could outcomes.
Язык: Английский
Процитировано
2
Advances in Therapy, Год журнала: 2024, Номер 41(7), С. 2606 - 2634
Опубликована: Май 14, 2024
Over the course of 2023, numerous key clinical trials with valuable contributions to cardiology were published or presented at major international conferences. This review seeks summarise these and reflect on their context. The authors collated reviewed conferences during 2023 including American College Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), Society (ESC), Transcatheter Therapeutics (TCT), Heart (AHA), Rhythm (EHRA), Angiography (SCAI), TVT-The Summit (TVT) Research Technologies (CRT). Trials a broad relevance community those potential change current practice included. A total 80 identified inclusion. Key in acute coronary syndrome (ACS) antiplatelet management such as HOST-IDEA, T-PASS STOP-DAPT3 included addition several pivotal interventional ORBITA 2, MULTISTARS-AMI, ILUMIEN-IV, OCTIVUS OCTOBER. Additionally, evaluated new stent design technology BIOSTEMI, PARTHENOPE TRANSFORM. Structural intervention long-term data from PARTNER 3, durability transcatheter aortic valve (TAVI), regarding tricuspid TRISCEND II. failure (HF) prevention covered studies DAPA-MI, STEP-HF, ADVOR, DICTATE HF CAMEO-DAPA. In cardiac devices electrophysiology, trial exploring novel ablation strategies atrial fibrillation (AF) PULSED AF ADVENT further evaluating efficacy anticoagulation subclinical NOAH-AFNET 6, FRAIL AZALEA-TIMI 71. article presents summary past year should be interest both practising clinicians researchers.
Язык: Английский
Процитировано
1